Baxter buys Oncaspar portfolio for $900M; Lilly readies $18M milestone for Hutchison;

@FierceBiotech: China's BeiGene banks $97M to get its cancer drugs into the clinic. Article | Follow @FierceBiotech

@JohnCFierce: No, the IPO flood won't float all boats. Gelesis scraps plans, for now, for a $52M IPO. More | Follow @JohnCFierce

> Baxter ($BAX) is acquiring the Oncaspar (pegaspargase) product portfolio from Sigma-Tau Finanziaria S.p.A. for $900 million. News

> Eli Lilly ($LLY) is set to make an $18 million milestone payment to Hutchison MediPharma, majority owned by Hutchison China MediTech, or Chi-Med, in the second quarter of 2015 after a positive first proof-of-concept study result for fruquintinib, a candidate for treatment of patients with metastatic colorectal cancer in China. Story

> AstraZeneca ($AZN) struck two deals to expand its R&D reach, teaming up with Abbott Laboratories ($ABT) to develop an asthma diagnostic and tapping the Montreal Heart Institute to examine more than 80,000 patients in hopes of better understanding the root causes of cardiovascular diseases. Item

> Soligenix ($SNGX) has teamed up with Emergent BioSolutions ($EBS) to develop a vaccine for ricin poisoning. More

Medical Device News

@FierceMedDev: FDA approves Roche's cancer diagnostic as a guide to use of Amgen, Lilly meds. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Lilly hopes new drug delivery R&D center will prove useful in osteoporosis, diabetes arenas. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Biogen's hot MS meds could push Pfizer off its CNS throne. Report | Follow @EmilyWFierce

> Glaucoma micro stent player Glaukos files to raise up to $86M in an IPO. Story

> Seattle hospital sues Olympus over duodenoscope devices tied to superbug outbreak. Article

Pharma News

@FiercePharma: Phibro records strong sales growth despite industry shift from antibiotics. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Alexion expanding in Ireland. Will spend $506M on its first biologics plant outside of U.S. News from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Endo plots a relaunch of Auxilium's ED med, complete with new salesforce and DTC. FiercePharmaMarketing report | Follow @CarlyHFierce

> Vertex eyes big revenue boost with FDA panel backing for Orkambi. More

> Senator asks VA to yank patent on Gilead's Sovaldi to crush its price. Report

Pharma Marketing News

> Wrongfully fired rep needs a real job offer, judge tells Bayer. And fork over that back pay, stat. More

> Want to know a secret? Pharma's patient services are going to waste. News

> Can pharma + tech wearables be a match made in patient heaven? Report

> Lucky 7 diabetes meds to join blockbuster club by 2020. Story

> Endo plots a relaunch of Auxilium's ED med, complete with new salesforce and DTC. More

Biotech Research News

> Moderna tops CNBC's list of most disruptive new technologies. Item

> VCU scientist preps gene therapy/drug combo for PhI prostate cancer study. Story

> Garvan team spotlights role of rogue cells in autoimmune diseases. Article

> Swift setback: A preclinical success in hep B is followed by safety woes. News

> Biopharma companies jump into the big data stampede for genetic triggers of disease. Report

Diagnostics News

> Soon-Shiong reels in $100M for cancer genomics unit. Item

> FDA approves Roche's cancer diagnostic as a guide to use of Amgen, Lilly meds. Story

> Navidea scores $60M loan to broaden reach for Lymphoseek. Article

> HTG Molecular Diagnostics unveils $50M IPO for genomic profiling technology. More

> Adaptive Biotechnologies reels in $195M for immunosequencing tech. News

Suggested Articles

The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new CMO.

On the heels of a merger and $60 million private offering, Compass is looking to go public. It filed to raise up to $50 million in its Nasdaq IPO.

he results suggest V114 provides broader protection from pneumococcal bacteria than Prevnar 13 does, positioning Merck to muscle in on Pfizer’s turf.